Which are the causes of 2q23.1 Microdeletion Syndrome?

2q23.1 Microdeletion Syndrome is a rare genetic disorder caused by the loss of a small segment of genetic material on the long arm of chromosome 2. This deletion typically occurs as a random, "de novo" event during the formation of reproductive cells or early embryonic development, rather than being inherited from a parent.

What causes 2q23.1 Microdeletion Syndrome?

The primary cause of 2q23.1 Microdeletion Syndrome is the absence of a specific region of DNA on chromosome 2. Within this deleted region lies the MBD5 gene (Methyl-CpG-binding domain protein 5), which is widely considered the critical gene responsible for the core features of the condition. Because this gene is essential for normal brain development and neurological function, its loss disrupts typical cognitive and physical growth.

Is 2q23.1 Microdeletion Syndrome hereditary?

In the vast majority of cases, 2q23.1 Microdeletion Syndrome is not inherited. It is a "de novo" (new) mutation, meaning it occurs spontaneously. While it is theoretically possible for a parent to carry a balanced chromosomal rearrangement that could lead to this deletion in offspring, clinical data shows that most individuals with 2q23.1 Microdeletion Syndrome have parents with normal chromosomal profiles. There are no known environmental, dietary, or lifestyle triggers that cause this deletion.

How does the deletion affect the body?

The loss of the MBD5 gene leads to a range of developmental impacts. While research is ongoing, clinicians have identified several key ways this genetic change manifests:

• Neurological impact: The MBD5 gene is crucial for regulating other genes involved in synaptic function and brain connectivity.


• Developmental delays: Most individuals experience significant speech delays and intellectual disabilities.


• Behavioral patterns: Many patients with 2q23.1 Microdeletion Syndrome exhibit features similar to Autism Spectrum Disorder or have specific motor skill challenges.


• Physical traits: Some individuals present with distinct facial features, small head size (microcephaly), or sleep disturbances.

What is the current state of research?

Medical researchers are currently studying how MBD5 interacts with other genomic pathways. Because 2q23.1 Microdeletion Syndrome is so rare, global databases like DiseaseMaps.org—which currently supports 4 members with this condition—are vital for researchers to aggregate clinical experiences and better understand the full spectrum of the etiology.

Next steps

• Consult a clinical geneticist for chromosomal microarray analysis to confirm the diagnosis.


• Connect with the 4 members of the 2q23.1 Microdeletion Syndrome community on DiseaseMaps.org for peer support.


• Work with a multidisciplinary team including speech therapists, neurologists, and physical therapists to manage developmental symptoms.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider.

References

• NIH Genetic and Rare Diseases Information Center (GARD): 2q23.1 microdeletion syndrome overview.


• Orphanet: MBD5-associated neurodevelopmental disorder (2q23.1 microdeletion).


• OMIM (Online Mendelian Inheritance in Man): Entry #613769 (MBD5-associated disorder).


• PubMed: Clinical studies on MBD5 haploinsufficiency and neurodevelopmental outcomes.